Benazeprilat

Research use only, not for human use.

Benazeprilat(CGS 14831) is an orally active active metabolite of Benazepril.Benazeprilat has potent antihypertensive activity and can be used in combination with other classes of compounds.

Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage.

——

Benazeprilat (10 mg/kg, intravenous injection) and amlodipine (0.5 mg/kg, intravenous injection) in combination produce great hypotensive effect.Benazepril (0.7 mg/kg, oral) markedly influences the dynamics of systemic RAAS peptides, resulting in a substantial decrease in AII and ALD while increasing PRA and AI.Animal Model:Male SHR (14-16 weeks of age, 250-350 g).Dosage:10 mg/kg Administration:I.V; once a day for 2 days.Result:Produced hypotensive effect.Animal Model:Beagle dogs (12.0-19.5 kg).Dosage:0.7 mg/kg Administration:P.O, once a day for 5 days.Result:Effected systemic RAAS peptides.

——

Endocrinology/Hormones

RAAS

RAAS | Endogenous Metabolite

——

——

86541-78-8

396.44

C22H24N2O5

>98% (HPLC)

——

C(C(O)=O)N1C=2C(CC[C@H](N[C@@H](CCC3=CC=CC=C3)C(O)=O)C1=O)=CC=CC2

——

(-20℃)

With Ice Pack

≥ 2 years